Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously.
The drug giant $(LLY)$ is also reducing the price of 2.5 mg and 5 mg vials of Zepbound, a treatment for diabetes or obesity, that has become highly popular with patients but has also been criticized for its high cost.
Lilly said it will lower the price of the 2.5 mg dose to $349 a month and cut the price of the 5 mg dose to $499 a month.
The company's new Zepbound Self Pay Journey Program offers the 7.5 mg and 10 mg doses at the new price with refills that come within 45 days of prior delivery.
Lilly's stock was up 0.8% premarket.
-Ciara Linnane
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
February 25, 2025 06:57 ET (11:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。